Cocrystal Pharma (COCP) Common Equity (2010 - 2026)

Cocrystal Pharma (COCP) has 17 years of Common Equity data on file, last reported at $4.1 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 43.65% year-over-year to $4.1 million; the trailing twelve-month figure through Mar 2026 stood at $4.1 million (down 43.65% YoY), and the FY2025 full-year result was $6.3 million, down 33.52% from the prior year.
• Common Equity fell to $4.1 million in Q1 2026, from $6.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $73.6 million in Q1 2022 to a low of $4.1 million in Q1 2026.
• A 5-year average of $25.4 million and a median of $22.6 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 41.34% in 2022 and tumbled 69.33% in 2025, its largest moves.
• Tracing COCP's Common Equity over 5 years: stood at $39.6 million in 2022, then tumbled by 33.37% to $26.4 million in 2023, then sank by 63.91% to $9.5 million in 2024, then slumped by 33.52% to $6.3 million in 2025, then tumbled by 34.99% to $4.1 million in 2026.
• Business Quant data shows COCP's Common Equity at $4.1 million in Q1 2026, $6.3 million in Q4 2025, and $7.7 million in Q3 2025.